Protein dysregulation in CSF reflects AD pathophysiology

Testing a panel of proteins in the cerebrospinal fluid (CSF) can help differentiate between early dementia, Alzheimer’s disease (AD), and non-AD dementia, researchers say.

“The development of disease-modifying therapies against AD requires biomarker panels that reflect the diverse pathological pathways specifically involved in AD,” noted Dr Marta Del Campo of the University Medical Centers Amsterdam, The Netherlands.